Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) was the target of a significant growth in short interest during the month of May. As of May 15th, there was short interest totalling 78,100 shares, a growth of 125.1% from the April 30th total of 34,700 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average daily trading volume, of 152,900 shares, the short-interest ratio is presently 0.5 days.

GANX has been the subject of a number of research analyst reports. B. Riley decreased their price objective on shares of Gain Therapeutics from $16.00 to $11.00 in a report on Monday, May 23rd. HC Wainwright began coverage on shares of Gain Therapeutics in a research note on Tuesday, March 29th. They issued a “buy” rating and a $12.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Gain Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research note on Wednesday.

A number of large investors have recently modified their holdings of GANX. Millennium Management LLC grew its stake in Gain Therapeutics by 66.2% during the second quarter. Millennium Management LLC now owns 23,878 shares of the company’s stock valued at $239,000 after acquiring an additional 9,511 shares in the last quarter. Veritable L.P. bought a new stake in Gain Therapeutics during the third quarter valued at approximately $187,000. UBS Group AG lifted its position in Gain Therapeutics by 64.4% during the third quarter. UBS Group AG now owns 6,740 shares of the company’s stock valued at $51,000 after purchasing an additional 2,640 shares during the last quarter. Telemetry Investments L.L.C. lifted its position in Gain Therapeutics by 217.7% during the third quarter. Telemetry Investments L.L.C. now owns 96,232 shares of the company’s stock valued at $716,000 after purchasing an additional 65,939 shares during the last quarter. Finally, CM Management LLC lifted its position in Gain Therapeutics by 39.9% during the fourth quarter. CM Management LLC now owns 90,000 shares of the company’s stock valued at $489,000 after purchasing an additional 25,673 shares during the last quarter. 8.89% of the stock is owned by institutional investors.

Shares of GANX traded up $0.17 during trading hours on Friday, hitting $2.89. The company’s stock had a trading volume of 91,749 shares, compared to its average volume of 118,818. The company has a market cap of $34.34 million, a price-to-earnings ratio of -2.37 and a beta of 0.35. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.63 and a quick ratio of 14.78. The business has a 50 day simple moving average of $3.56 and a two-hundred day simple moving average of $4.65. Gain Therapeutics has a 52-week low of $2.33 and a 52-week high of $10.90.

Gain Therapeutics (NASDAQ:GANX – Get Rating) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.06. The company had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.06 million. Gain Therapeutics had a negative net margin of 7,212.75% and a negative return on equity of 40.43%. Research analysts predict that Gain Therapeutics will post -1.33 earnings per share for the current year.

Gain Therapeutics Company Profile (Get Rating)

Gain Therapeutics, Inc, a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.

Featured Stories